Synendos Therapeutics develops a class of small molecules for the treatment of anxiety and stress-related disorders.
Synendos Therapeutics's investors include HTGF (High-Tech Gruenderfonds), Kurma Partners, Ysios Capital, Zürcher Kantonal Bank, Venture Kick.
Synendos Therapeutics is headquartered in Allschwil, Switzerland.
Synendos Therapeutics develops a class of small molecules for the treatment of anxiety and stress-related disorders.
Synendos Therapeutics is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Synendos Therapeutics — Funding & Investors." VCBacked, September 1, 2025, https://www.vcbacked.co/company/synendos-therapeutics. Accessed August 15, 2026.
VCBacked. (2025). Synendos Therapeutics — Funding & Investors. Retrieved August 15, 2026, from https://www.vcbacked.co/company/synendos-therapeutics
{{cite web |title=Synendos Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/synendos-therapeutics |website=VCBacked |access-date=August 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated